Remember that in my first post I said that the BLOG would encompass Pharma marketing, branding, ideas and inspiration. Well this falls into the inspiration column. I am a huge Tim Burton fan. So the news below has got me pretty excited. It comes out in March, 2010 so all I can say is…please God [...]
This is what I call must-see TV. Andreeson is an internet legend and 14 years after launching the first viable internet browser, he is still bringing it. To watch the interview just click on the Charlie Rose link in my links list and navigate to the Andreeson interview.
You might also enjoy the interview of Mickey [...]
A new book on healthcare has been published which I can’t wait to read. Health Communication and the New Media Landscape has just been published. I will read it this week and publish a thorough BLOG providing a good synopsis of my key observations and implications. Should anyone want to grab it themselves here is [...]
I attended a conference on Twitter this past weekend. Met some interesting people including Seth Greenberg of Intuit, Stephanie Nelson of Dell, Laura Fitton (The Twitter guru), Guy Kawasaki (Evangelism Expert), Bob Pearson of The Blog Council among others. Pics of the presenters and moderators are just below.
The conference was well organized and well hosted. [...]
To what extent do we go to draw attention to an issue? I think Pfizer UK, in the development of the commercial below, has created a new formula for addressing that question. The more serious the issue, the farther it’s appropriate to go to draw attention to it.
In this case we have a quite serious [...]
Pharma take note. Twitter is rapidly blowing past facebook and even BLOGs as a medical communications channel. These stats just in from Ed Bennet a hospital manager from Maryland who has an interest in tracking these things.
Notes from Ed Bennett, a Hospital Web Manager
Hospital Social Network Data & Charts
This page provides links to the spreadsheets [...]
Daiichi Sankyo Gets FDA Approval For AZOR(R) – First-Line Treatment for High Blood Pressure
Daiichi Sankyo, Inc. has announced that the FDA has approved the combination treatment AZOR(R) (amlodipine and olmesartan medoxomil) as initial or ‘first-line’ therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure (BP) goals. The FDA approval [...]